

Substitute for Form 1449/PTO


INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/501,964
Filing Date	May 19, 2005
First Named Inventor:	Sang-Kyou Lee
Art Unit	1647
Examiner Name	Cherie Michelle Woodward
Attorney Docket Number	007157.P002



1

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/501,964
				Filing Date	May 19, 2005
				First Named Inventor:	Sang-Kyou Lee
				Art Unit	1647
				Examiner Name	Cherie Michelle Woodward
Sheet	2	of	3	Attorney Docket Number	007157.P002
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	1	STERNSON, L.A., "Obstacles to Polypeptide Delivery," 1987, pages 19-21, Annals of N.Y. Acad. Sci., 57, (1987)			
	2	HOFFMANN, P. ET AL., "Stimulation of Human and Murine Adherent Cells by Bacterial Lipoprotein and Synthetic Lipopeptide Analogues," 1988, pgs. 158-170, Immunobiol., Vol.177, 1988			
	3	SHEN, WEI-CHIANG ET AL., "Conjugation of poly-L-lysine to albumin and horseradish peroxidase: A novel method of enhancing the cellular uptake of proteins," April 1978, pages 1872-1876, Proc. Natl. Acad. Sci. USA 75 No. 4, April 1978			
	4	PRIOR, TREVOR I. ET AL., "Barnase Toxin: A New Chimeric Toxin Composed of Pseudomonas Exotoxin A and Barnase," March 8, 1991, pages 1017-1023, Cell Vol. 64, Cell Press, 1991			
	5	FAWELL, STEPHEN ET AL., "Tat-mediated delivery of heterologous proteins into cells," January 1994, pgs 664-668, Proc. Natl. Acad. Sci. USA Vol. 91, 1994			
	6	ELLIOTT, G. ET AL., "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein," January 24, 1997, pages 223-233, Cell Vol. 88, Cell Press, 1997			
	7	SCHWARZE, S. R. ET AL., "In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA," 2000, pgs 45-48, Trends Pharmacol. Sci., Vol. 21, (2000)			
	8	LAUS, R. ET AL., "Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides," December 2000, pgs. 1269-1272, Nature Biotechnol., Vol. 18, Nature America Inc., 2000			
	9	BECKER-HAPAK, M. ET AL., "TAT-Mediated Protein Transduction into Mammalian Cells," 2001, pages 247-256, Methods 24, Academic Press, 2001			
	10	ROTHBARD, JB, ET AL., "Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation," November 2000, pages 1253-1257, Nature Med., 2000 Nov;6(11), Nature America Inc., 2000			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/501,964
				Filing Date	May 19, 2005
				First Named Inventor:	Sang-Kyou Lee
				Art Unit	1647
				Examiner Name	Cherie Michelle Woodward
Sheet	3	of	3	Attorney Docket Number	007157.P002
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	11	ALKEMA, M.J ET AL., "Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex," 1997, pgs. 226-240, Genes Dev. 11, Cold Spring Harbor Laboratory Press, 1997			
	12	SCHMID, I. ET AL., Dead Cell Discrimination With 7-Amino-Actinomycin D in Combination With Dual Color Immunofluorescence in Single Laser Flow Cytometry, 1992, pgs. 204-208, Cytometry Vol.13, Wiley-Liss, Inc. 1992			
	13	SIM, JAE-HYUCK ET AL., "Immunosuppressive effects of tautomycin in vivo and in vitro T cell-specific apoptosis induction," August 6, 2002, pgs. 10617-10622, PNAS vol. 99, no. 16, 2002			
	14	GUNSTER, MJ. ET AL., "Identification and Characterization of Interactions between the Vertebrate Polycomb-Group Protein BMI1 and Human Homologs of Polyhomeotic," April 1997, pgs 2326-35, Mol. And Cell Bio. Vol. 17, No. 4, American Society of Microbiology, 1997			
	15	OHTA, H. ET AL., "Structure and Chromosomal Localization of the RAE28/HPH1 Gene, a Human Homologue of the Polyhomeotic Gene," 2000, pgs. 61-73, DNA Sequence 2000; 11(1-2), Overseas Publishers Association N. V. , 2000			
	16	YAMAKI, A, ET AL., "The Mammalian Single-Minded (SIM) Gene: Mouse cDNA Structure and Diencephalic Expression Indicate a Candidate Gene for Down Syndrome," 1996, pgs. 136-43, Genomics Vol. 35, Article No. 0332, Academic Press, 1996			
	17	CHRAST, R., ET AL., "Cloning of Two Human Homologs of the Drosophila single-minded Gene SIM1 on Chromosome 6q and SIM2 Within the Down Syndrome Chromosomal Region," 1997 Jul, 7(6), pgs. 615-24, Genome Research, Cold Spring Harbor Laboratory Press, 1997			
	18	OSOEGAWA, K., ET AL., "A 19-kb CpG Island Associated with Single-minded Gene 2 in Down Syndrome Chromosomal Region," 1996 Jun. 30, 3(3), pgs. 175-9, DNA Research 3, 1996			
	19	YAMAKI, A ET AL, "Molecular mechanisms of human single-minded 2 (SIM2) gene expression: identification of a promoter site in the SIM2 genomic sequence," GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL. Vol.270, no.1-2, pp.265-275, 30 May 2001.			

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Based on Form PTO/SB/08B (08-03) as modified by BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP on 09/10/03.